Glucose-6-Phosphate Dehydrogenase (G6PD) Gene Mutation Analysis
Glucose-6-phosphate dehydrogenase (G6PD) is expressed in all cells and is a key enzyme in the hexose monophosphate (HMP) shunt (also known as pentose phosphate pathway) which is critical for the generation of NADPH and ribose sugars for nucleic acid synthesis. NADPH plays a crucial role in keeping glutathione in the reduced state for detoxification of reactive oxygen species (ROS) in order to prevent oxidative damage. In red blood cells, NADPH is produced exclusively via the HMP and is important in maintaining cellular membrane integrity and preventing premature destruction.
The G6PD gene is located on the long (q) arm of the X chromosome at position 28 (Xq28). It spans 18kb and consists of 13 exons of which exon 1 is noncoding. G6PD deficiency is the most common enzyme deficiency worldwide, affecting approximately 400 million people. Incidence is particularly high in Kurdish Jewish males (7 in 10), African American males (1 in 6 to 10), Arabic males (1 in 7 to 9) and Southeast Asian males (1 in 6 to 16). G6PD variants have been grouped into four categories by WHO classification and based on the level of residual enzyme activity and clinical manifestations as shown below:
- I Severe deficiency associated with chronic hemolytic anemia, <10% enzyme activity
- II Severe deficiency without hemolytic anemia (e.g G6PD Mediterranean), <10% enzyme activity
- III Moderate to mild deficiency (e.g. G6PD A-), 10% - 60% enzyme activity
- IV No deficiency (e.g. wild type), Normal enzyme activity
- V Increased enzyme activity Increased, > 2x enzyme activity
More than 400 variants and over 200 different mutations in the G6PD gene have been described. The most common mutation in persons of African descent is G6PD (A-), characterized by an Asn-to-Asp substitution at codon 126 (c.376A>G) which in most cases is also accompanied by a second mutation encoding a Val-to-Met change at codon 68 (c.202G>A). The mutation seen most commonly in individuals of Mediterranean descent is G6PD (Med), in which there is a Ser-to-Phe substitution at codon 188 (c.563C>T).
Most individuals with G6PD deficiency are asymptomatic but can develop acute hemolysis under oxidative stress due to certain drugs (antimalarials, antipyretic analgesics, sulfonamides, sulfones, nitrofurans, etc.), infections, or the ingestion of fava beans (favism). Since RBCs exclusively rely on G6PD activity for the generation of NADPH, G6PD-deficient RBCs are unable to withstand oxidative damage and are susceptible to destruction. The degree of hemolysis that may occur is dependent on the degree of G6PD deficiency and may either cause mild anemia, or acute severe anemia and jaundice which can be life threatening. Therefore, assessment of G6PD enzyme activity is recommended in at risk patients before administering drugs that are known to induce hemolysis in G6PD deficiency. Enzyme activity is measured by determining the rate of conversion of NADP to NADPH from a hemolysate of the patient’s blood. It is important to recognize that the G6PD content of red cells decreases over time with higher levels in reticulocytes and lower levels in aged red cells. During a hemolytic episode the older more deficient red cells hemolyze first and the bone marrow responds by increasing red cell production and reticulocytosis. Therefore, it is critical to NOT test patients suspected of G6PD deficiency after an acute hemolytic event as increased G6PD in the reticulocytes may mask the deficiency (false negative result). Once a deficiency of G6PD is established, genotyping is rarely necessary but may help in the classification of patients (esp. those of Chinese ancestry) and their risk of adverse effects to oxidant drugs.
In some cases, as a result of skewed X-chromosome inactivation (lyonization), heterozygous females may be susceptible to the same pathophysiological phenotype as their hemizygous male counterparts. Only small proportion of individuals with G6PD deficiency demonstrate phenotypes of chronic nonspherocytic hemolytic anemia (CNSHA). Mutation associated with G6PD deficiency in CNSHA are generally clustered in exons 10 and 11 and are characterized by severe deficiency of G6PD with chronic hemolysis even without additional oxidative stress.
- Aid in the diagnosis of glucose-6-phosphate dehydrogenase (G6PD) deficiency
- Identification of individuals at risk for drug-induced acute hemolytic anemia associated with G6PD deficiency
- Useful to rule out G6PD deficiency in neonates with jaundice of unknown origin
- Aid in the diagnosis of chronic nonspherocytic hemolytic anemia (CNSHA)
- Carrier and prenatal screening in families at risk
Erythrocytes: 0.117-0.143 U/million cells.
Whole blood (EDTA or citric acid), Saliva.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: Unacceptable
- Lancet. 2008;371(9606):64-74. [PMID: 18177777]
- Int J Mol Sci. 2016;17(12):2069. [PMID: 27941691]
- Am J Hematol. 1996 Jan;51(1):19-25. [PMID: 8571933]
- Hematol Oncol Clin North Am. 2016;30(2):373-93. [PMID: 27040960]
- Blood. 1994;84(11):3613-36. [PMID: 7949118]
- Solinge WW, Wijk R. Enzymes of the red blood cell. Textbook of Clinical Chemistry and Molecular Diagnostics. 6th ed. 2018. Page 435.e1-e19.